Nebenwirkungen · Amgevita
AMGEVITA 20 mg solution for injection in pre-filled syringe AMGEVITA 40 mg solution for injection in pre-filled syringe AMGEVITA 80 mg solution for injection in pre-filled syringe AMGEVITA 40 mg solution for injection in pre-filled pen AMGEVITA 80 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 76
HOS-224958 · Präparat HOS-217372
When combining controlled portions of these trials and ongoing and completed open-label extension studies of adalimumab, with a median duration of approximately 3.3 years including 6 427 patients and over 26 439 patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin cancers is approximately 8.5 per 1 000 patient-years. The observed rate of non-melanoma skin cancers is approximately 9.6 per 1 000 patient-years, and the observed rate of lymphomas is approximately 1.3 per 1 000 patient-years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T02:00:00Z · SHA-256 e60d722f3b6745489b45f5c78ae97b6371cdaa2129d753a34a831ca4ba40a8b5 · Passage b995f338d8b9f2c0769d43db0d2328a24b869959a2b08475b7356e7e3787611b · Zeichen 18540–19082 im Abschnitt